Tarsus Pharmaceuticals, Inc. TARS Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$66.42M+42.5% | -$115.55M+15.0% | -$135.89M-119% | -$62.09M-349% | ||
| $822K+24.2% | $662K-11.9% | $751K+126% | $332K+6.4% | ||
| $41.72M+50.0% | $27.82M+40.3% | $19.83M+47.3% | $13.46M+59.2% | ||
| $593K+23.0% | $482K+25.2% | $385K+24.6% | $309K— | ||
| —— | —— | $16.62M— | —— | ||
| $1.79M— | —— | $3.11M— | —— | ||
| —— | —— | $7.73M+184% | $2.72M+54.8% | ||
| $527K+186% | -$614K-186% | $718K+234% | $215K— | ||
| -$1.72M-124% | $7.02M+143% | $2.89M+301% | $721K— | ||
| $881K+63.1% | $540K+440% | $100K— | —— | ||
| —— | —— | —— | —— | ||
| —— | -$83.03M+29.3% | -$117.49M-140% | -$49.03M— | ||
| $9.86M+529% | $1.57M+4.3% | $1.5M+197% | $506K-13.7% | ||
| $393.19M+49.7% | $262.63M— | —— | $149.44M— | ||
| —— | -$202.32M-244% | $140.6M+197% | -$144.63M-24,581% | ||
| —— | —— | —— | —— | ||
| $143.39M-7.3% | $154.66M+18.8% | $130.18M+38.3% | $94.12M— | ||
| —— | -$127.57M-182% | $155.01M+256% | -$99.67M— | ||
| $8.34M+8.9% | $7.66M+166% | $2.88M+71.9% | $1.68M— | ||
| —— | —— | —— | —— | ||
| $5.48M+30.1% | $4.21M+33.2% | $3.16M+140% | $1.32M— | ||
| $593K+23.0% | $482K+25.2% | $385K+24.6% | $309K— | ||
| $881K+63.1% | $540K+440% | $100K— | —— | ||
| $822K+24.2% | $662K-11.9% | $751K— | —— | ||
| —— | —— | $7.73M+184% | $2.72M+54.8% | ||
| —— | —— | —— | —— | ||
| —— | $37.79M+334% | $8.7M— | —— | ||
| —— | —— | —— | —— | ||
| -$1.72M-124% | $7.02M+143% | $2.89M+301% | $721K— | ||
| $682K+7.4% | $635K+17.4% | $541K+16.6% | $464K— | ||
| $1.53M+1,446% | $99K-26.1% | $134K— | —— | ||
| $0— | —— | $0— | $0— | ||
| $0-100% | $1.08M— | $0— | $0— | ||
| —— | —— | —— | —— | ||
| —— | -$84.59M+28.9% | -$119M-140% | -$49.54M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Tarsus Pharmaceuticals, Inc. generate?
- Tarsus Pharmaceuticals, Inc. (TARS) generated -$96.9M in operating cash flow over the trailing twelve months.
- What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
- After $15.1M of capital expenditures, Tarsus Pharmaceuticals, Inc.'s free cash flow was -$104.4M over the trailing twelve months, down 2.6% year over year.
- Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
